Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.
NCT00298623 is registered in ClinicalTrials.gov with XenoPort, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.
- Lead sponsor
- XenoPort, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 2006
- Completion date
- February 28, 2007
- Enrollment
- 222 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.